EGFR and non-small cell lung carcinoma: In preclinical models, metformin suppresses oncogenic pathways such as EGFR signaling, insulin-like growth factor, and acts as a radiation sensitizer in NSCLC by activating AMPK, suppressing mTOR, and inducing G1 cell-cycle arrest (98, 127–129).